Sexually Transmitted Infection Screening

Sexually transmitted infection (STI) screening is the systematic testing of sexually active people who have no symptoms for infections such as chlamydia, gonorrhoea, syphilis, and others, in order to detect and treat infection early and to limit its spread. Because many of these infections are commonly asymptomatic yet can cause serious complications, screening is a central preventive activity in sexual and reproductive health.

Definition

STI screening is the application of laboratory or point-of-care tests to asymptomatic, sexually active individuals to identify sexually transmitted infections before symptoms or complications arise, as a form of secondary prevention.

Scope

This topic covers the rationale and structure of STI screening: why asymptomatic infections are sought, how target populations are defined (for example by age, sex, pregnancy status, and behavioural risk), and the broad categories of tests used, with nucleic-acid amplification testing for chlamydia and gonorrhoea and serologic testing for syphilis as the principal examples. It addresses screening as a reference concept and does not specify whom to test, screening intervals, or treatment, which are set by current guidelines.

Core questions

• Which sexually transmitted infections are common enough and detectable enough to justify screening asymptomatic people?
• How are screening populations and intervals defined for chlamydia, gonorrhoea, and syphilis?
• What test types underpin STI screening and how do screening and confirmatory testing differ?
• How does screening reduce both individual complications and population transmission?

Key concepts

• Asymptomatic infection
• Nucleic-acid amplification testing (NAAT)
• Serologic (treponemal and nontreponemal) testing for syphilis
• Risk-based and age-based screening
• Reinfection and repeat screening
• Partner notification
• Pelvic inflammatory disease as a downstream complication

Mechanisms

Chlamydial and gonococcal infections are frequently asymptomatic, particularly in women, yet can ascend to cause pelvic inflammatory disease, infertility, and ectopic pregnancy; screening detects these silent infections so that they can be treated before complications develop. Nucleic-acid amplification tests, which can be performed on urine or self-collected swabs, give STI screening high sensitivity and make it feasible at scale. Syphilis screening uses a sequence of treponemal and nontreponemal serologic tests, reflecting the staged natural history of the infection. By identifying and treating asymptomatic carriers, screening also shortens the period of infectiousness and, combined with partner notification, interrupts transmission chains.

Clinical relevance

STI screening recommendations determine which asymptomatic patients are offered testing in primary care, sexual-health, and antenatal services, and understanding the underlying logic supports appraisal of those recommendations. This entry explains the purpose and structure of screening as a preventive activity; decisions about whom to test, how often, and how to treat are governed by current clinical guidelines and are outside its scope.

Epidemiology

Chlamydia and gonorrhoea are among the most frequently reported notifiable infections worldwide, with the highest burden in adolescents and young adults, and syphilis has re-emerged in several populations. A large proportion of these infections are asymptomatic, which is the central reason screening is recommended for defined groups. Specific recommendations — for example routine screening of sexually active younger women for chlamydia and gonorrhoea, and risk-based syphilis screening — are set out in the cited guidelines.

History

Screening for sexually transmitted infection has roots in twentieth-century syphilis serology programmes, but the modern era was transformed by the introduction of nucleic-acid amplification tests for chlamydia and gonorrhoea in the 1990s, which allowed sensitive, non-invasive testing of asymptomatic people. National task-force and public-health guidelines, periodically updated, have since codified which populations to screen and how reinfection should be managed.

Seminal works

• uspstf-chlamydia-gonorrhea-2021
• workowski-cdc-sti-2021

Frequently asked questions

Why screen for sexually transmitted infections if there are no symptoms?

Infections such as chlamydia and gonorrhoea are often silent but can still be transmitted and can cause complications like pelvic inflammatory disease and infertility; screening finds them so they can be treated early.

What kinds of tests are used to screen for STIs?

Chlamydia and gonorrhoea are typically screened with nucleic-acid amplification tests on urine or swabs, while syphilis is screened using a sequence of blood (serologic) tests; reactive screening results are confirmed before diagnosis.